More tools:Markets·Screener·Research Chat

Idexx Laboratories Inc (IDXX) Financial Statements

Idexx Laboratories Inc
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S5S4Y9
XNAS · usd
540.68▼ 23.53 (-4.17%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$4.4B
Net Income (TTM)$1.1B
EBITDA
Diluted EPS (TTM)
EBITDA Margin35.0%
Net Debt
Trading Information
Previous Close564.21
Day's Range536.14 – 559.60
52-Week Range506.91 – 769.98
Volume753.0K
Avg Volume655.2K
Share Statistics
Shares Outstanding78.9M
Employees11.0K
ExchangeXNAS
Listed1991-06-21

Key questions about Idexx Laboratories Inc (IDXX)

What is Idexx Laboratories Inc's Market Cap?
Idexx Laboratories Inc's Market Cap is $42.7B, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's Enterprise Value?
Idexx Laboratories Inc's Enterprise Value is $44.8B, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's Trailing P/E?
Idexx Laboratories Inc's Trailing P/E is 38.9×, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's Price / Sales?
Idexx Laboratories Inc's Price / Sales is 9.6×, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's EV / Revenue?
Idexx Laboratories Inc's EV / Revenue is 10.1×, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's EV / EBITDA?
Idexx Laboratories Inc's EV / EBITDA is 28.8×, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's Revenue (TTM)?
Idexx Laboratories Inc's Revenue (TTM) is $4.4B, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's Net Income (TTM)?
Idexx Laboratories Inc's Net Income (TTM) is $1.1B, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's EBITDA?
Idexx Laboratories Inc's EBITDA is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is Idexx Laboratories Inc's Diluted EPS (TTM)?
Idexx Laboratories Inc's Diluted EPS (TTM) is 13.88, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenue:
Product revenue
Service revenue
Total revenue
YoY growth+14.3%+14.3%+13.3%+10.6%
Cost of Revenue:
Cost of product revenue
Cost of service revenue
Total cost of revenue
Gross profit
% of revenue63.4%60.3%61.8%62.6%
Expenses:
Sales and marketing
General and administrative
Research and development
Total operating expenses
% of revenue31.6%31.4%29.7%29.0%
Income (loss) from operations
% of revenue31.8%28.9%32.1%33.6%
Interest expense
Interest income
Income (loss) before income taxes
Income tax expense (benefit)
Net income (loss)
% of revenue24.4%22.8%24.8%26.5%
Earnings per Share:
Basic
Diluted
Weighted Average Shares Outstanding:
Basic
Diluted